<MedlineCitation Status="Completed">
<MedlineID>10011170</MedlineID>
<PMID>33681</PMID>
<DateCreated>
<Year>1979</Year>
<Month>04</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>04</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2001</Year>
<Month>11</Month>
<Day>02</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0004-3591</ISSN>
<JournalIssue>
<Volume>22</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1979</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Alteration of lymphocyte function in NZB/NZW mice. IV. Response to levamisole.</ArticleTitle>
<Pagination>
<MedlinePgn>236-42</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>NZB/NZW F1 female mice received levamisole in an attempt to increase suppressor T cell function. Responses varied with dosage of drug and age of mice. When treatment with 25 microgram/gm doses (intermittent or daily) was begun at 12 weeks of age, nephritis was accelerated in spite of transient reduction of anti-DNA antibodies. When treatment was begun at 4 weeks, or when doses of 250 microgram/gm were given, no clinical effects were observed. In the mice with accelerated disease, delayed hypersensitivity and antibody responses to sheep erythrocytes increased; antibody responses to pneumococcal polysaccharide were unaffected. It is possible that some increased immune responses associated with levamisole are undesirable in murine lupus.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Hahn</LastName>
<ForeName>B H</ForeName>
<Initials>BH</Initials>
</Author>
<Author>
<LastName>Knotts</LastName>
<ForeName>L L</ForeName>
<Initials>LL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Arthritis Rheum</MedlineTA>
<NlmUniqueID>0370605</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Antibodies, Antinuclear</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Immunoglobulin M</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>14769-73-4</RegistryNumber>
<NameOfSubstance>Levamisole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Antibodies, Antinuclear</DescriptorName>
<QualifierName>analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Glomerulonephritis</DescriptorName>
<QualifierName>drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName>mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Graft vs Host Reaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hypersensitivity, Delayed</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Immune Complex Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Immunoglobulin M</DescriptorName>
<QualifierName>analysis</QualifierName>
<QualifierName>biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Levamisole</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Lupus Erythematosus, Systemic</DescriptorName>
<QualifierName>drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
<QualifierName>mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Mice, Inbred NZB</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Spleen</DescriptorName>
<QualifierName>immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
